1-7 of 7
Authors: Shunta Hori
Journal Article
Long-term clinical outcomes after salvage radiotherapy in patients with biochemical recurrence after radical prostatectomy Get access
Japanese Journal of Clinical Oncology, hyaf037, https://doi.org/10.1093/jjco/hyaf037
Published: 26 February 2025
Journal Article
Duration of α-1 adrenergic antagonist administration after low-dose-rate brachytherapy for prostate cancer Get access
Japanese Journal of Clinical Oncology, Volume 54, Issue 12, December 2024, Pages 1343–1350, https://doi.org/10.1093/jjco/hyae113
Published: 28 August 2024
Journal Article
Enfortumab vedotin following platinum-based chemotherapy and immune checkpoint inhibitors for advanced urothelial carcinoma: response, survival and safety analysis from a multicentre real-world Japanese cohort Free
Japanese Journal of Clinical Oncology, Volume 54, Issue 3, March 2024, Pages 329–338, https://doi.org/10.1093/jjco/hyad170
Published: 07 December 2023
Journal Article
Clinical practice of UroVysion® urine test in patients with bladder carcinoma in situ treated with intravesical Bacillus Calmette–Guerin Free
Japanese Journal of Clinical Oncology, Volume 53, Issue 7, July 2023, Pages 629–632, https://doi.org/10.1093/jjco/hyad029
Published: 10 April 2023
Journal Article
The Japanese health care system-based cost-effectiveness of photodynamic diagnosis-assisted transurethral resection of bladder tumor for non-muscle invasive bladder cancer Free
Japanese Journal of Clinical Oncology, Volume 53, Issue 4, April 2023, Pages 343–348, https://doi.org/10.1093/jjco/hyac203
Published: 30 December 2022
Journal Article
Switch-maintenance avelumab immunotherapy following first-line chemotherapy for patients with advanced, unresectable or metastatic urothelial carcinoma: the first Japanese real-world evidence from a multicenter study Free
Japanese Journal of Clinical Oncology, Volume 53, Issue 3, March 2023, Pages 253–262, https://doi.org/10.1093/jjco/hyac186
Published: 08 December 2022
Journal Article
Prostate-specific antigen bounce after 125I-brachytherapy for prostate cancer is a favorable prognosticator in patients who are biochemical recurrence-free at 4 years and correlates with testosterone Get access
Japanese Journal of Clinical Oncology, Volume 50, Issue 1, January 2020, Pages 58–65, https://doi.org/10.1093/jjco/hyz136
Published: 28 October 2019
